Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069680 · ClinicalTrials.gov registry record
Genetic Analysis of Gray Platelet Syndrome
A clinical trial of Myelofibrosis and Genetic Linkage, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 123
- Enrollment target
- 1
- Study location
NCT00069680 is a study of Myelofibrosis and Genetic Linkage that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 123 participants, below the 194-participant average among 61 other Myelofibrosis trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00069680, a study of Myelofibrosis and Genetic Linkage, has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 123 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will identify and characterize the gene or genes responsible for Gray Platelet syndrome (GPS). Platelets are small blood cells that stick on injured blood vessels to form a plug and stop bleeding. When a blood vessel is injured (like a cut on a finger), platelets release the proteins stored in their sacs to help form a blood clot. Patients with GPS bleed longer than other people because their platelets lack some of these protein-carrying sacs. Platelets without sacs look pale gray under the microscope rather than pink, giving the syndrome its name. Except for rare patients with severe hemorrhage, the bleeding tendency in GPS is usually mild to moderate, with patients experiencing easy bruising, nosebleeds, and, in women, excessive menstrual bleeding. Patients with GPS and members of their family with GPS may be eligible for this study. Participants will provide a personal and family medical history and will have blood drawn. About 1 to 2 tablespoons of blood will be drawn in adults, and about 1 teaspoon in children. The blood will be analyzed for genes that cause GPS
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2003-09-29 |
| Est. Completion | 2018-05-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00069680
The ClinicalTrials.gov registry entry for NCT00069680 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 194-participant average among 61 other Myelofibrosis trials with a reported enrollment target (37% lower). The listed sponsor is National Human Genome Research Institute (NHGRI), which has 185 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT00069680 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00069680 about?
NCT00069680 is a clinical study titled "Genetic Analysis of Gray Platelet Syndrome". This study will identify and characterize the gene or genes responsible for Gray Platelet syndrome (GPS). Platelets are small blood cells that stick on injured blood vessels to form a plug and stop bleeding. When a blood vessel is injured (like a cut on a finger), platelets release the proteins stor...
What is the current status of trial NCT00069680?
This trial is currently completed. The enrollment target is 123 participants. The study started on 2003-09-29. Estimated completion is 2018-05-17.
What conditions does trial NCT00069680 study?
This clinical trial studies the following conditions: Myelofibrosis, Genetic Linkage.
Who is sponsoring clinical trial NCT00069680?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00069680 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 3
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.